Form 4 Filing for MoonLake Immunotherapeutics - Director Catherine Moukheibir Acquires Options
2026-06-18SEC Filing 4 (0001213900-26-070256)
This filing details a Form 4 submission for MoonLake Immunotherapeutics (MLTX), reporting a transaction by director Catherine Moukheibir. On June 17, 2026, Ms. Moukheibir acquired an option to purchase 22,195 Class A ordinary shares. The option has a strike price of $19.19 and will vest fully on either June 17, 2027, or the date of the Issuer's next annual general meeting, contingent upon her continued service. This acquisition is classified as direct ownership. The filing was signed on June 18, 2026, by Matthias Bodenstedt as attorney-in-fact for Ms. Moukheibir.